November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at email@example.com)
May 22, 2015
Rostelecom might reconsider dividend policy in favor of increase
EU visa-free travel for Ukraine, Georgia dependent on their compliance with terms - commissioner
Cherkizovo more than doubles net profit in Q1 to 2.1 bln rubles - company
Saiga antelope death toll may reach 85,000 in Kazakhstan's Kostanai region - Agriculture Ministry
Kyiv is still denying Russian consular officials access to two Russians detained in Donbas - Russian Foreign Ministry
Russian monetary base down 2.3 bln rubles
CHERKIZOVO MORE THAN DOUBLES US GAAP NET PROFIT IN Q1 TO 2.1 BLN RUBLES - COMPANY
RUSSIAN MONETARY BASE WAS AT 7965.2 BLN RUBLES ON MAY 15, DOWN FROM 7967.5 BLN RUBLES ON MAY 8 - CB
DPR Defense Ministry reports overnight bombardment of Horlivka
Bank Rossiya requesting to participate in program to recapitalize through OFZ - Moiseyev
MICEX and RTS Indexes at 11:00 MSK
Ukraine to demand Russian pay $48 bln to compensate for companies' losses in Crimea - Justice Ministry
Polymetal to refinance part of debt due in 2016 to 2018
Inquiry opened into May 21 clashes in central Kyiv